Bruce Belanger
Public Health Agency of Canada(CA)Atea Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Lung Cancer Research Studies, Colorectal Cancer Treatments and Studies, Cancer therapeutics and mechanisms, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial(2015)1,174 cited
- → NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors(2019)309 cited
- → Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B(2009)195 cited
- → Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer(2017)54 cited
- → NAPOLI-1: Randomized Phase 3 Study of MM-398 (NAL-IRI), with or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin, in Metastatic Pancreatic Cancer Progressed on or Following Gemcitabine-Based Therapy(2014)52 cited
- → First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study(2021)51 cited
- → Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin(2018)49 cited
- → 736 Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-Interferon in treatment-naïve patients with HCV-1 infection: First results from a phase IIb trial(2006)46 cited
- → Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study(2019)45 cited
- → Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase(2020)44 cited